Oncology Support Care.
Conditions we treat
- Solid tumor chemotherapy administration in collaboration with referring oncologists
- Hematologic malignancy supportive care
- Anti-emetic and supportive medication management
- Bone modifying agent administration
- Iron and blood product supportive care
Oncology support therapies we deliver
TheraVite Health delivers and manages oncology supportive care therapies that help patients tolerate chemotherapy, manage bone metastases, and complete their treatment regimens. We coordinate closely with each patient’s oncology team.
Infusion therapies (in-suite administration)
- Keytruda (pembrolizumab) — IV anti-PD-1 immunotherapy
- Opdivo (nivolumab) — IV anti-PD-1 immunotherapy
- Herceptin (trastuzumab) and biosimilars — IV anti-HER2
- Avastin (bevacizumab) and biosimilars — IV anti-VEGF
- Zometa (zoledronic acid) — IV bisphosphonate
- Aloxi (palonosetron), Emend (fosaprepitant), Sustol — IV anti-emetics
Subcutaneous therapies (specialty pharmacy dispensing)
- Phesgo (pertuzumab + trastuzumab + hyaluronidase) — SC anti-HER2 combination
- Xgeva (denosumab) — SC RANK ligand inhibitor for bone metastases
- Neulasta, Udenyca, Fulphila (pegfilgrastim) — long-acting G-CSF
- Aranesp (darbepoetin alfa), Procrit (epoetin alfa) — ESAs for chemotherapy-induced anemia
What makes TheraVite’s approach distinct
TheraVite operates in close collaboration with the patient’s oncology team. Treatment plans, dose modifications, and lab monitoring remain under the prescribing oncologist’s direction — TheraVite handles administration, supportive care, prior authorization, and benefits investigation. Patients on long-term immunotherapy (Keytruda, Opdivo) or HER2 therapy (Herceptin, Phesgo) often appreciate TheraVite’s shorter wait times and quieter setting compared to large hospital infusion centers, while remaining fully connected to their oncology care team.
For referring providers
TheraVite handles prior authorization, benefits investigation, and payor credentialing for all therapies listed above. For drugs subject to limited distribution networks, we are pursuing manufacturer access in parallel with URAC accreditation. Contact us for current access status by drug.
For patients
If you have been prescribed any of the therapies above, TheraVite can typically begin treatment within 5 to 10 business days of receiving your prescription. We handle insurance verification, prior authorization, and patient onboarding so you can focus on your therapy.